Related Experiment Video

Updated: Mar 7, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.2K

A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer

Liang Ouyang1, Lan Zhang1, Leilei Fu1

  • 1a State Key Laboratory of Biotherapy and Cancer Center , West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy , Chengdu , China.

Autophagy
|February 7, 2017
PubMed

Insights

This study identifies a new small-molecule activator, LYN-1604, that targets ULK1 (unc-51 like autophagy activating kinase 1) to induce autophagy-associated cell death. This offers a potential new therapeutic strategy for triple-negative breast cancer (TNBC).

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Autophagy, initiated by ULK1 (unc-51 like autophagy activating kinase 1), is a key cellular process.
  • Activation of ULK1-modulated autophagy-associated cell death (ACD) presents a potential therapeutic avenue for triple-negative breast cancer (TNBC).

Purpose of the Study:

  • To investigate ULK1 as a drug target for TNBC.
  • To identify and characterize a novel small-molecule activator of ULK1.

Main Methods:

  • Integrated analysis of The Cancer Genome Atlas (TCGA) data.
  • Tissue microarray-based analyses.
  • Biologic evaluations of ULK1 interactors and ACD.

Main Results:

  • Demonstrated a novel small-molecule activator of ULK1 (LYN-1604).
  • Elucidated ULK1's role in regulating ACD via the ULK complex and interactors (ATF3, RAD21, CASP3) in TNBC.
  • LYN-1604 exhibits anti-tumor activity and modulates ACD.

Conclusions:

  • ULK1 is a viable drug target for TNBC.
  • The ULK1 activator LYN-1604 shows promise as a candidate drug for TNBC therapy due to its anti-tumor and ACD-modulating properties.
Keywords:
ULK1 activatorUNC-51-like kinase 1 (ULK1)autophagyautophagy-associated cell death (ACD)triple negative breast cancer (TNBC)

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.5K

Related Concept Videos

Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.1K